Table 2.
Comparison of etiological factors and outcome according to the RHRF (-) group or the RHRF (+) group.
| Compared data | RHRF (-) | RHRF (+) | p | ||
|---|---|---|---|---|---|
| n = 453% | n = 324% | ||||
| Infections | |||||
| Paracranial (focal) systemic | 20 | 4 | 13 | 4 | 0.963 |
| 7 | 2 | 5 | 2 | ||
| History of VTE | |||||
| Cerebral | 11a | 2 | 2a | 0.6 | |
| Deep venous thrombosis | 14a | 3 | 3b | 1 | 0.024 |
| Other | 6a | 1 | 2a | 0.6 | |
| Malignancy | 32 | 7 | 1 | 0.3 | <0.001 |
| Family history VTE | 5 | 1 | 1 | 0.3 | 0.409 |
| MTHFR mutation | |||||
| Heterozygote | 19 | 7 | 9 | 4 | 0.120 |
| Homozygote | 24 | 8 | 9 | 4 | |
| Hyperhomocysteinemia | 12 | 3 | 9 | 3 | 0.952 |
| Prothrombin mutation | 5 | 2 | 7 | 3 | 0.249 |
| Protein C/S deficiency | 25 | 7 | 13 | 5 | 0.302 |
| Factor V Leiden mutation | 11 | 4 | 11 | 5 | 0.405 |
| Thrombocytosis | 2 | 0.5 | 2 | 1 | 0.753 |
| Polycythemia vera | 3 | 1 | 0 | 0 | 0.267 |
| Anticardiolipin Ab | 2 | 0.5 | 1 | 0.4 | 0.752 |
| PAI mutation | 4 | 1 | 2 | 1 | 0.681 |
| Antithrombin III deficiency | 3 | 1 | 1 | 0.4 | 0.642 |
| Hyperfibrinogenemia | 0 | 0 | 2 | 1 | 0.178 |
| Antiphospholipid Ab | 7 | 2 | 4 | 2 | 0.767 |
| Activated protein C | 5 | 1 | 4 | 2 | 0.892 |
| Resistance | 13 | 4 | 4 | 2 | 0.114 |
| High ANA titers | |||||
| First month Rankin | |||||
| 0-1 | 304 | 80 | 236 | 81 | 0.276 |
| 2 | 40 | 11 | 37 | 13 | |
| >3 | 38 | 10 | 20 | 7 | |
| Third month Rankin | |||||
| 0-1 | 287 | 89 | 227 | 91 | |
| 2 | 21 | 7 | 17 | 7 | 0.235 |
| >3 | 15 | 5 | 5 | 2 | |
| Sixth month Rankin | |||||
| 0-1 | 262 | 90 | 215 | 96 | |
| 2 | 16 | 6 | 6 | 3 | 0.061 |
| >3 | 13 | 5 | 4 | 2 | |
| 12th month Rankin | |||||
| 0-1 | 239 | 91 | 185 | 97 | |
| 2 | 11 | 4 | 4 | 2 | 0.031 |
| >3 | 13 | 5 | 2 | 1 | |
ANA: antinuclear antibody; MTHFR: methylenetetrahydrofolate reductase; PAI: plasminogen activator inhibitor; VTE: venous thromboembolism.